BridgeBio keeps FDA approval spree rolling, this time with nod for targeted bile duct cancer med

BridgeBio is keeping the momentum going in 2021. After winning a nod for its rare disease med Nulibry earlier this year, the FDA has handed the company an approval for its targeted cancer treatment.